9 Million Doses of Cuban Abdala Vaccine To Reach Mexico

In Mexico, over 96.8 million people have received at least one dose, representing 82 percent of the total population, said Hugo Lopez-Gatell, Undersecretary of Prevention and Health Promotion. Sep 6, 2022.

Published 6 September 2022

Opinion

The West and the Majority World - Repression Versus Openn...

by teleSUR/MS

Texas National Guard on the border with Mexico, 2024.

Migration, Trump, Biden and What is to Come

by Jose Cabañas Rodriguez

This is part of the plan to immunize 15.3 million children between 5 and 11 years of age against COVID-19.

On Tuesday, the Mexican government announced the purchase of 9 million doses of the Cuban vaccine Abdala for the immunization against COVID-19 of children between 5 and 11 years of age.

RELATED:

López Obrador Announces Resumption of Work on the Maya Train

The Undersecretary of Prevention and Health Promotion, Hugo López-Gatell, said that "with 9 million doses that, given that it is a three-dose scheme, will be enough for 3 million girls and boys."

López-Gatell did not specify the date the doses will arrive or the contract amount. According to the official, the Abdala vaccine is part of the scheme contemplated to immunize 15.3 million children aged 5 to 11 years old.

This will also include Pfizer's nearly 8 million doses, almost 800 000 donated by South Korea and 10 million from WHO's Covax mechanism.

Avanza la vacunación contra #COVID19, particularmente entre la población infantil. Al 06 de septiembre la cobertura es de:

- 82% en personas de todas las edades.
- 91% de 18 años y más.
- 64% de 12 a 17 años.
- 46% de 5 a 11 años. pic.twitter.com/IcojfJLJm2
— Hugo López-Gatell Ramírez (@HLGatell) September 6, 2022

Vaccination against #COVID19 , particularly among children. As of September 6, the coverage is:

- 82% in people of all ages.
- 91% of 18 years and over.
- 64% from 12 to 17 years old.
- 46% from 5 to 11 years.

According to López-Gatell, in Mexico over 96.8 million people have received at least one dose, representing 82 percent of the total population.

The World Health Organization (WHO) has not yet endorsed the Cuban vaccine. Mexico was one of the first countries in the world to authorize its emergency use last December.

The Abdala vaccine was created and manufactured by the Center for Genetic Engineering and Biotechnology (CIGB). Approved by Cuba last year, it has demonstrated 92.28 percent efficacy in clinical trials, according to Cuban authorities, who indicated that the latest phase of tests involved 48 000 volunteers aged 19 to 80 years.